Stock EVAX EVAXION BIOTECH A/S
Add to a list
To use this feature you must be a member
Log inSign up

Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 12:11:35 2024-05-24 EDT 		5-day change 1st Jan Change
4.1 USD +5.67% Intraday chart for Evaxion Biotech A/S +10.21% -40.21%
05:54pm European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower MT
11:10am Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Evaxion Biotech A/S

European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower MT
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment MT
Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 CI
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Evaxion Biotech A/S Elects Lars Staal Wegner as A New Board Member CI
Evaxion Announces Phase 2 Clinical Trial Update CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
ADRs End Lower; Meta Data Slides 22% DJ

Chart Evaxion Biotech A/S

Chart Evaxion Biotech A/S
More charts

Company Profile

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Sector
Biotechnology & Medical Research
Calendar
2024-05-29 - Nordic Digital Science & Innovation Day
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.88 USD
Average target price
11.75 USD
Spread / Average Target
+202.84%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EVAXION BIOTECH A/S Stock Evaxion Biotech A/S
-40.21% 20.99M
MODERNA, INC. Stock Moderna, Inc.
+68.62% 62.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.93% 41.38B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.38B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.64B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.81% 26.46B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.24% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.22% 12.67B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.13% 12.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.99% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EVAX Stock
  4. News Evaxion Biotech A/S
  5. Evaxion Biotech to Target Non-Small Cell Lung Cancer With Drug Candidate; Shares Rise Pre-Bell